Moberg Pharma AB Year-end report 2018
MAJOR TRANSFORMATION OF THE COMPANY AFTER A STRONG YEAR This year-end report 2018 is made public in advance due to the transaction press release announced earlier today regarding the divestment of Moberg Pharma’s OTC-business.PERIOD (FULL YEAR 2018) · Net revenue SEK 439.0 million (439.0, current portfolio 369.2). Current portfolio growth of 16%* · EBITDA SEK 101.7 million (89.4) including, and SEK 96.7 million (76.4) excluding, capital gains** · EBITDA margin 23% (20) · EBITDA for commercial operations SEK 123.1 million (106.0) · Operating profit (EBIT) SEK 64.8 million